Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis

被引：61

作者：

Bhise, Nupura S. ^{[1
]}

Shmueli, Ron B. ^{[1
]}

Sunshine, Joel C. ^{[1
]}

Tzeng, Stephany Y. ^{[1
]}

Green, Jordan J. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21231 USA

来源：

EXPERT OPINION ON DRUG DELIVERY | 2011年 / 8卷 / 04期

关键词：

ENDOTHELIAL GROWTH-FACTOR; SUPERPARAMAGNETIC IRON-OXIDE; LIPOSOMES IN-VIVO; TUMOR ANGIOGENESIS; GENE DELIVERY; MACULAR DEGENERATION; CONTROLLED-RELEASE; DOUBLE-BLIND; UNILAMELLAR LIPOSOMES; VASCULAR-PERMEABILITY;

D O I：

10.1517/17425247.2011.558082

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Areas covered: This paper reviews the basic biology of angiogenesis, including current knowledge about its disruption in diseases, with the focus on cancer and AMD. Anti- and proangiogenic drugs available for clinical use or in development are also discussed, as well as experimental drug delivery systems that can potentially improve these therapies to enhance or reduce angiogenesis in a more controlled manner. Expert opinion: Laboratory and clinical results have shown pro- or antiangiogenic drug delivery strategies to be effective in drastically slowing disease progression. Further research in this area will increase the efficacy, specificity and duration of these therapies. Future directions with composite drug delivery systems may make possible targeting of multiple factors for synergistic effects.

引用

页码：485 / 504

页数：20

共 201 条

[1]

Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy [J].

Abdollahi, Amir ;

Folkman, Judah .

DRUG RESISTANCE UPDATES, 2010, 13 (1-2) :16-28

[2]

Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model [J].

Abu-Lila, Amr ;

Suzuki, Takuya ;

Doi, Yusuke ;

Ishida, Tatsuhiro ;

Kiwada, Hiroshi .

JOURNAL OF CONTROLLED RELEASE, 2009, 134 (01) :18-25

[3]

THERAPY OF LEISHMANIASIS - SUPERIOR EFFICACIES OF LIPOSOME-ENCAPSULATED DRUGS [J].

ALVING, CR ;

STECK, EA ;

CHAPMAN, WL ;

WAITS, VB ;

HENDRICKS, LD ;

SWARTZ, GM ;

HANSON, WL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (06) :2959-2963

[4]

Ambati, J ;

Ambati, BK ;

Yoo, SH ;

Ianchulev, S ;

Adamis, AP .

SURVEY OF OPHTHALMOLOGY, 2003, 48 (03) :257-293

[5]

Foreign body reaction to biomaterials [J].

Anderson, James M. ;

Rodriguez, Analiz ;

Chang, David T. .

SEMINARS IN IMMUNOLOGY, 2008, 20 (02) :86-100

[6]

Biodegradation and biocompatibility of PLA and PLGA microspheres [J].

Anderson, JM ;

Shive, MS .

ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24

[7]

[Anonymous], 2007, BIOL CANC

[8]

Bae YH, 2000, ADV DRUG DELIVER REV, V42, P1

[9]

Bang YJ, 2010, LANCET, V376, P1302

[10]

Synthesis and characterization of a fluvastatin-releasing hydrogel delivery system to modulate hMSC differentiation and function for bone regeneration [J].

Benoit, Danielle S. W. ;

Nuttelman, Charles R. ;

Collins, Stuart D. ;

Anseth, Kristi S. .

BIOMATERIALS, 2006, 27 (36) :6102-6110

← 1 2 3 4 5 6 7 8 9 10 →